FDA approved a 2-dose schedule of hepatitis B vaccination for adolescents
On Aug. 29, 1999, Merck, West Point, Pennsylvania) received approval from the FDA of a supplement to Merck’s license application to include the manufacture of single-antigen preservative-free hepatitis B vaccine (Recombivax HBﾮ, Pediatric); distribution is expected to begin Sept. 13, 1999.
In addition, SmithKline Beecham (Philadelphia, Pennsylvania), expected to make single-antigen preservative-free hepatitis B vaccine (Engerix-Bﾮ, Pediatric) available in the near future.
Tags:
Source: U.S. Centers for Disease Control and Prevention
Credit:
